Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Additional information Prior Presentation: This manuscript is based on work that was presented at the American Diabetes Association83rd Annual Scientific Sessions, San Diego, CA, USA, 2326 June 2023: 769-P: Effect of food on the pharmacokinetics, safety and tolerability of orforglipron (LY3502970) an oral, non-peptide GLP-1 receptor agonist
Real-world evidence from UK and European databases suggests that patients with type 2 diabetes and fatty liver who receive GLP-1 therapy experience improvements in liver enzyme levels (ALT, AST) and non-invasive markers of fibrosis
Improved cardiovascular risk: GLP-1 therapy can lead to improvements in cardiometabolic risks, with some benefits appearing even before substantial weight loss, notes ScienceDirect.com
What are the side effects of oral GLP-1 medicines
June 1, 2023
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
